About

Company description

Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025.  It works with innovator pharma and biotech companies across USA, EU & Japan, accelerating the discovery, development and manufacture of complex small molecules. Over the past two decades, Sai Life Sciences has consistently delivered on a diverse set of NCE development programs for its customers with a track record of bringing value based on quality, pricing and responsiveness. Today, as one of India’s fastest growing CDMO companies, Sai Life Sciences works with the leading large pharma companies, as well as several small and mid-sized pharma & biotech companies. Sai Life Sciences is backed by committed long-term investors, TPG Capital and HBM Healthcare Investments.

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Advanced Intermediates |Analytical Chemistry |Analytical Chemistry More

Upcoming events

30 sep 2020

CPhI Japan 2020

30 September - 2 October 2020 Osaka, Japan Visit us at stand 1C-50 Book a meeting See our Exhibitor Profile   See full Exhibitor List
13 oct 2020

CPhI Worldwide 2020

13 - 15 October 2020 Milan, Italy Visit us at stand 7F60 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 101B50 See our Exhibitor Profile   See full Exhibitor List
18 mar 2019

CPhI Japan 2019

18 - 20 March 2019 Tokyo, Japan We were at stand 2F-29 See our Exhibitor Profile   See full Exhibitor List

News about Sai Life Sciences

Sai Life Sciences joins the global ‘COVID Moonshot’ project

8 May 2020

Sai Life Sciences joins the global ‘COVID Moonshot’ project

Sai Life Sciences, today announced its collaboration with the COVID Moonshot project that aims to deliver an antiviral drug candidate effective against COVID-19. With an in-kind contribution of a team of Medicinal Chemists and supporting infrastructure, Sai Life Sciences will help synthesize and profile analogues for NCEs and other previously known compounds tested for other viruses.

Read more

25 Apr 2020

Responding to the COVID-19 pandemic

Since the outbreak of the COVID-19, Sai Life Sciences has been taking several proactive measures to protect its employees and their families, and to minimize the impact on its partners, customers and the community.

Read more

25 Apr 2020

AAALAC International renews full accreditation to Sai Life Sciences for its laboratory animal care and use program

As a validation of our commitment to maintaining the highest standards in animal care and compliance with industry and regulatory guidelines, the Sai Life Sciences discovery facility in Pune recently received a renewed accreditation for its laboratory animal care and use program from AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care) International.

Read more

9 Apr 2020

Making sanitizers available during COVID-19 outbreak

Over the past few weeks since the outbreak of COVID-19, there’s been a sudden rise in sanitization efforts by various public and private organizations to help arrest the spread of the disease. This, along with efforts of individuals in their own spaces, has created a huge demand for effective alcohol-based sanitizers to aid the sanitization efforts.

Read more